Skip to content

Court urges data‑driven assessment before invoking Section 100 on expensive cancer medicines

By News Analysis India · · 1 min read

While the court did not order the immediate application of Section 100 in the case of costly breast‑cancer drugs, it instructed the Centre to gather relevant data to determine affordability and to consider intervention where necessary. The directive focuses on collecting price, usage and accessibility statistics before any compulsory licensing or government‑authorized use is pursued.